Hospital Center of Entre o Douro e Vouga, Rua Dr Candido Pinho, 4520-220 Santa Maria da Feira, Portugal.
Faculty of Medicine of University of Porto, Porto, Portugal.
Ther Adv Cardiovasc Dis. 2022 Jan-Dec;16:17539447221132908. doi: 10.1177/17539447221132908.
Heart failure (HF) is a syndrome increasing worldwide, and literature shows that the hospitalizations are associated with greater mortality rates. A patient-centered method combined with optimized medical treatment and palliative care may improve HF outcomes, and some advocate a multifaceted approach to achieve a perfect management of chronic HF (CHF).
The objective of this study was to present the study protocol of GENICA project which aims to optimize the ambulatory approach of CHF patients, and reduce their re-hospitalization, emergency readmission, and global death rate.
Prospective cohort including patients referred to HF consultation and collecting sociodemographic, clinical, and analytical variables among others. The outcomes will be mortality, re-hospitalization, and emergency readmission rates. The association between the independent variables and outcomes will be assessed by logistic regression. Comparison between GENICA patients and controls will be made by χ test. Significance at level of less than 0.05.
GENICA will offer a wide range of longitudinal data with evidence that will influence future healthcare of CHF patients at an ambulatory basis.
GENICA will provide practical evidence of real HF patient's profile and develop workable decision algorithms, which will influence future ambulatory care of CHF. HF patients will be safer at home and will keep stability for longer periods, consuming less health resources and slow the progression of the disease. Being a matched cohort, GENICA benefits from an accuracy similar to that of randomized controlled trials, without the need to perform a rigorous allocation of the intervention. Being prospective there's no problem about response bias.
CHF should be approached with a multidisciplinary and multifaceted strategy privileging the outpatient setting, including home monitoring, and GENICA is the paramount protocol enabling this. GENICA may come to show health policy makers that the asset is not to divide and rule, but to converge strategies, therapies, and knowledge.
心力衰竭(HF)是一种在全球范围内不断增加的综合征,文献表明住院与更高的死亡率相关。患者为中心的方法结合优化的医疗和姑息治疗可能改善 HF 的结果,并且一些人主张采用多方面的方法来实现慢性 HF(CHF)的完美管理。
本研究旨在介绍 GENICA 项目的研究方案,该项目旨在优化 CHF 患者的门诊治疗方法,降低其再住院率、紧急再入院率和全球死亡率。
前瞻性队列研究,纳入 HF 咨询患者,收集社会人口统计学、临床和分析等变量。结局将是死亡率、再住院率和紧急再入院率。通过逻辑回归评估独立变量与结局之间的关系。将 GENICA 患者与对照组进行 χ 检验比较。显著水平为 0.05 以下。
GENICA 将提供广泛的纵向数据,这些证据将影响未来 HF 患者在门诊基础上的医疗保健。
GENICA 将提供真实 HF 患者特征的实用证据,并制定可行的决策算法,这将影响未来 HF 的门诊护理。HF 患者在家中会更安全,并且会保持更长时间的稳定,消耗更少的医疗资源并减缓疾病的进展。作为匹配队列,GENICA 受益于类似于随机对照试验的准确性,而无需进行严格的干预分配。由于是前瞻性研究,不存在响应偏差的问题。
CHF 应采用多学科和多方面的策略,优先考虑门诊环境,包括家庭监测,而 GENICA 是实现这一目标的首要方案。GENICA 可能会向卫生政策制定者表明,关键不是分而治之,而是汇聚策略、疗法和知识。